Positioning ceftazidime-avibactam in managing difficult-to-treat P. aeruginosa infections in critically ill patients
11 Jan 2025
In a Pfizer-sponsored webinar reaching audiences in Malaysia, Singapore, Indonesia, and the Philippines, Dr Alex Soriano, Consultant in Infectious Diseases at the Clinical and Provincial Hospital of Barcelona, Spain, discussed the pivotal role of ceftazidime/avibactam in treating multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) infections in critically ill patients.
Resources
Positioning ceftazidime-avibactam in managing difficult-to-treat P. aeruginosa infections in critically ill patients
Positioning ceftazidime-avibactam in managing difficult-to-treat P. aeruginosa infections in critically ill patients